Echtzeit-Aktienkurs GenMark Diagnostics Inc.
Bid:
Ask:
Echtzeit-Chart der GenMark Diagnostics Inc. Aktie
Fundamentaldaten der GenMark Diagnostics Inc. Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2020 [USD] | 171,55 Mio. | -18,56 Mio. | -18,64 Mio. | -0,28 | - | - | - |
| 2019 [USD] | 88,02 Mio. | -47,29 Mio. | -47,35 Mio. | -0,82 | - | - | - |
| 2018 [USD] | 70,76 Mio. | -50,36 Mio. | -50,50 Mio. | -0,91 | - | - | - |
| 2017 [USD] | 52,52 Mio. | -61,75 Mio. | -61,85 Mio. | -1,21 | - | - | - |
| 2016 [USD] | 49,27 Mio. | -50,50 Mio. | -50,60 Mio. | -1,15 | - | - | - |
| 2015 [USD] | 39,41 Mio. | -42,16 Mio. | -42,20 Mio. | -1,00 | - | - | - |
| 2014 [USD] | 30,59 Mio. | -38,84 Mio. | -38,26 Mio. | -0,93 | - | - | - |
| Die Multiples wie die KGVs werden mit der Bilanzwährung und dem Kurs des ausgewählten Börsenplatzes berechnet. Wählen Sie den Börsenplatz mit der Bilanzwährung aus, damit die Multiples korrekt sind. Die fundamentalen Daten werden von Facunda geliefert; Multiples werden mit dem aktuellen Kurs berechnet. | |||||||
Profil der GenMark Diagnostics Inc. Aktie
GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. Its XT-8 System has received 510(k) clearance from the United States Food and Drug Administration (FDA) and is designed to support a range of molecular diagnostic tests with a compact workstation and self-contained, disposable test cartridges. Within 30 minutes of receipt of an amplified deoxyribonucleic acid (DNA) sample, its XT-8 System produces results. The XT-8 System supports up to 24 test cartridges, which can be run independently, and are targeted for hospitals and reference laboratories. The Company is also developing its next-generation platform, the AD-8 System, to integrate DNA amplification with its sensor detection technology to enable technicians to place a minimally prepared patient sample into its test cartridge.